These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35085246)

  • 1. Role of interferon-induced GTPases in leishmaniasis.
    Lipoldová M; Sohrabi Y
    PLoS Negl Trop Dis; 2022 Jan; 16(1):e0010093. PubMed ID: 35085246
    [No Abstract]   [Full Text] [Related]  

  • 2. Resolution of an infection with Leishmania braziliensis confers complete protection to a subsequent challenge with Leishmania major in BALB/c mice.
    Lima HC; DeKrey GK; Titus RG
    Mem Inst Oswaldo Cruz; 1999; 94(1):71-6. PubMed ID: 10029914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mannose receptor during experimental leishmaniasis.
    Akilov OE; Kasuboski RE; Carter CR; McDowell MA
    J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice.
    Rocha FJ; Schleicher U; Mattner J; Alber G; Bogdan C
    Infect Immun; 2007 Aug; 75(8):3823-32. PubMed ID: 17517868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
    Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
    Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages.
    Conrad SM; Strauss-Ayali D; Field AE; Mack M; Mosser DM
    Infect Immun; 2007 Feb; 75(2):653-65. PubMed ID: 17088347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice.
    Anderson CF; Mendez S; Sacks DL
    J Immunol; 2005 Mar; 174(5):2934-41. PubMed ID: 15728505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment of macrophages with the combination of IFN-gamma and IL-12 induces resistance to Leishmania major at the early phase of infection.
    Ota H; Takashima Y; Matsumoto Y; Hayashi Y; Matsumoto Y
    J Vet Med Sci; 2008 Jun; 70(6):589-93. PubMed ID: 18628599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic expression of CXCR3 on T cells enhances susceptibility to cutaneous Leishmania major infection by inhibiting monocyte maturation and promoting a Th2 response.
    Oghumu S; Stock JC; Varikuti S; Dong R; Terrazas C; Edwards JA; Rappleye CA; Holovatyk A; Sharpe A; Satoskar AR
    Infect Immun; 2015 Jan; 83(1):67-76. PubMed ID: 25312956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.
    de Moura TR; Novais FO; Oliveira F; Clarêncio J; Noronha A; Barral A; Brodskyn C; de Oliveira CI
    Infect Immun; 2005 Sep; 73(9):5827-34. PubMed ID: 16113301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cellular immunity and vaccination against cutaneous leishmaniasis. Recent progress and prospects].
    Carrada Bravo T
    Rev Alerg; 1993; 40(4):98-105. PubMed ID: 8143026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does lipophosphoglycan enhance the T cell-stimulatory activity of lipophosphoglycan-associated proteins?
    Mendonça SC; De-Luca PM; Olafson RW; Jardim A; Coutinho SG
    Braz J Med Biol Res; 1994 Feb; 27(2):553-7. PubMed ID: 8081281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-gamma-independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA.
    von Stebut E; Belkaid Y; Nguyen B; Wilson M; Sacks DL; Udey MC
    J Invest Dermatol; 2002 Sep; 119(3):621-8. PubMed ID: 12230504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two biochemically distinct lipophosphoglycans from Leishmania braziliensis and Leishmania infantum trigger different innate immune responses in murine macrophages.
    Ibraim IC; de Assis RR; Pessoa NL; Campos MA; Melo MN; Turco SJ; Soares RP
    Parasit Vectors; 2013 Mar; 6():54. PubMed ID: 23497381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of antigen-presenting cell type and interferon-gamma on priming and cytokine secretion of Leishmania major-specific T cells.
    Shankar AH; Titus RG
    J Infect Dis; 1997 Jan; 175(1):151-7. PubMed ID: 8985210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunology of murine leishmaniasis.
    McSorley S; Proudfoot L; O'Donnell CA; Liew FY
    Clin Dermatol; 1996; 14(5):451-64. PubMed ID: 8889322
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of the immune responses of mice to infection with Leishmania braziliensis.
    DeKrey GK; Lima HC; Titus RG
    Infect Immun; 1998 Feb; 66(2):827-9. PubMed ID: 9453649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine.
    Schwarz T; Remer KA; Nahrendorf W; Masic A; Siewe L; Müller W; Roers A; Moll H
    PLoS Pathog; 2013; 9(6):e1003476. PubMed ID: 23825956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.